Participation in the 11th International University-Business Network Congress, within the framework of the 50th anniversary of the Vice-Rectory for Research of the University of Costa Rica.
One of the most outstanding topics at the event was the Latin American pride in successfully taking research from the laboratory to the biopharmaceutical industry. In this context, researchers from the Clodomiro Picado Institute presented a unique development and technology transfer model in Latin America and the University of Costa Rica, focused on human plasma fractionation.
This model has enabled the development of advanced solutions for the production of hemoderivative drugs, such as immunoglobulin and human albumin, essential drugs, but difficult to access in the region, used for the treatment of complex, rare and orphan diseases. The proposed revolutionary method not only ensures greater safety in the process, but also offers higher yields than the traditional method, resulting in more accessible and safer drugs for critically ill patients.
Basic research at the University of Costa Rica laid the groundwork for the development of applied research, becoming the seed of great scientific and technological discoveries in the biopharmaceutical field.
Lifefactors gave a masterful presentation on the current state of progress and maturity of this technology, showing how it has managed to turn an academic technological study into an integral pharmaceutical solution for the region. A highlight was the development of the two-phase plasma fractionation method, which has allowed the construction of a pioneering plant in Rionegro, Antioquia, Colombia, with a fractionation capacity of 65,000 liters of plasma per year. In addition, it was announced that the construction of a plant at industrial level with a fractionation capacity of 650,000 liters per year is in process, destined to supply the growing demand of the region. This speech was made by Dr. Sergio Pulido, Lifefactors' Executive Director of Research, Development and Innovation.
This initiative represents a clear example of how the transformative power of science can become a tangible reality, providing innovative solutions for human health and demonstrating the impact of collaboration between academia and the biopharmaceutical industry.
Comments